论文部分内容阅读
目的探讨二甲双胍联合比格列酮治疗2型糖尿病临床效果。方法 2009年1月至2011年1月诊治的符合入选标准2型糖尿病患者162例,采取二甲双胍联合比格列酮治疗。结果本组病例分别于用药前和用药后6个月检测空腹血糖(FPG)、餐后2 h血糖(P2 hBG)、糖化血红蛋白(HbA1 c)三酰甘油(TC)、总胆固醇(TG)检测,并进行比较,P<0.05有统计学差异。结论二甲双胍联合比格列酮治疗2型糖尿病具有作用机制互补、提高疗效和减少不良反应,降糖作用显著的优点。
Objective To investigate the clinical effect of metformin combined with bevlitazone in the treatment of type 2 diabetes mellitus. Methods Between January 2009 and January 2011, 162 patients with type 2 diabetes mellitus who met the criteria of inclusion were treated with metformin and beaglitazone. Results The patients were tested for fasting blood glucose (FPG), postprandial 2h blood glucose (P2hBG), glycosylated hemoglobin (HbA1c) triglyceride (TC) and total cholesterol (TG) , And compared, P <0.05 statistically significant. Conclusions Metformin combined with bevacizin in the treatment of type 2 diabetes mellitus has the advantages of complementary mechanism of action, improvement of curative effect, reduction of adverse reactions and significant hypoglycemic effect.